ATE471315T1 - Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten - Google Patents
Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheitenInfo
- Publication number
- ATE471315T1 ATE471315T1 AT02773770T AT02773770T ATE471315T1 AT E471315 T1 ATE471315 T1 AT E471315T1 AT 02773770 T AT02773770 T AT 02773770T AT 02773770 T AT02773770 T AT 02773770T AT E471315 T1 ATE471315 T1 AT E471315T1
- Authority
- AT
- Austria
- Prior art keywords
- 17beta
- androgen
- piperidine
- treatment
- type
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 title 1
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 title 1
- VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical compound NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33006601P | 2001-10-17 | 2001-10-17 | |
| PCT/US2002/032979 WO2003033487A1 (en) | 2001-10-17 | 2002-10-15 | Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE471315T1 true ATE471315T1 (de) | 2010-07-15 |
Family
ID=23288179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02773770T ATE471315T1 (de) | 2001-10-17 | 2002-10-15 | Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6969718B2 (de) |
| EP (1) | EP1436281B1 (de) |
| JP (1) | JP4309761B2 (de) |
| CN (1) | CN1571782A (de) |
| AR (1) | AR036812A1 (de) |
| AT (1) | ATE471315T1 (de) |
| CA (1) | CA2463626C (de) |
| DE (1) | DE60236743D1 (de) |
| ES (1) | ES2347643T3 (de) |
| MX (1) | MXPA04003611A (de) |
| PE (1) | PE20030705A1 (de) |
| WO (1) | WO2003033487A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004046111A1 (en) | 2002-11-18 | 2004-06-03 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| MXPA05006485A (es) | 2002-12-17 | 2005-08-26 | Schering Corp | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno. |
| GB0314733D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| TW200528110A (en) * | 2003-12-17 | 2005-09-01 | Schering Corp | Pharmaceutical compositions |
| JP2007515490A (ja) * | 2003-12-22 | 2007-06-14 | アムジェン インコーポレーティッド | アリールスルホンアミド化合物およびそれに関連する使用法 |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| US7851474B2 (en) * | 2005-08-02 | 2010-12-14 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| WO2014207311A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
| KR20160042873A (ko) | 2013-06-25 | 2016-04-20 | 포렌도 파마 리미티드 | 17.베타.-하이드록시스테로이드 탈수소효소의 억제제로서 치료적 활성 17-질소 치환된 에스트라트리엔티아졸 유도체 |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| US10626140B2 (en) | 2014-12-23 | 2020-04-21 | Forendo Pharma Ltd | Prodrugs of 17β-HSD1-inhibitors |
| FI3634975T3 (fi) | 2017-06-08 | 2024-05-03 | Organon R&D Finland Ltd | 15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa |
| EP3724178B1 (de) | 2017-12-15 | 2024-05-01 | Inthera Bioscience AG | 1-(piperidinocarbonylmethyl)-2-oxopiperidin-derivate zur behandlung von krebs |
| BR112021010598A2 (pt) | 2018-12-05 | 2021-08-24 | Forendo Pharma Ltd | Compostos, método para preparação de um composto e composição farmacêutica |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| DE2304154A1 (de) | 1973-01-29 | 1974-08-01 | Ichthyol Ges Cordes Hermanni & | Verfahren zur herstellung von substituierten piperazin- bzw. homopiperazinderivaten |
| DE2304153A1 (de) * | 1973-01-29 | 1974-08-01 | Ichthyol Ges Cordes Hermanni & | Substituierte piperazin- und homopiperazinderivate |
| DE3586053D1 (de) | 1984-08-02 | 1992-06-17 | Labrie | Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs. |
| ES2077675T3 (es) | 1989-03-10 | 1995-12-01 | Endorecherche Inc | Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos. |
| ATE269066T1 (de) | 1989-07-07 | 2004-07-15 | Endorech Inc | Kombinationstherapie zur prophylaxe und/oder behandlung von gutartiger prostatischer hyperplasie |
| HUT60139A (en) | 1989-07-07 | 1992-08-28 | Endorecherche Inc | Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen |
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| CA2093798C (en) * | 1990-10-10 | 2000-02-01 | John J. Piwinski | Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and methods of use thereof |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| ATE140224T1 (de) * | 1992-03-27 | 1996-07-15 | Schering Corp | Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung |
| AU678409B2 (en) | 1992-10-28 | 1997-05-29 | Merck Sharp & Dohme Limited | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| US5661162A (en) | 1992-12-14 | 1997-08-26 | Merck Sharp & Dohme Limited | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists |
| SK139194A3 (en) | 1993-05-17 | 1995-07-11 | Endorecherche Inc | The improved antiandrogens |
| JPH08511522A (ja) | 1993-06-07 | 1996-12-03 | メルク エンド カンパニー インコーポレーテッド | ニューロキニンアンタゴニストとしてのスピロ置換アザ環 |
| IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| ATE170174T1 (de) * | 1994-01-13 | 1998-09-15 | Merck Sharp & Dohme | Gem-bissubstituierte azazyclische tachykinin- antagonisten |
| MX9707561A (es) | 1995-04-07 | 1997-12-31 | Schering Corp | Compuestos de carbonil piperazinilo y piperidinilo. |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5688960A (en) * | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| US5719156A (en) * | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5696267A (en) * | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5654316A (en) * | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| US5892039A (en) * | 1995-08-31 | 1999-04-06 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US5691362A (en) * | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| US5789422A (en) * | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
| US5968929A (en) * | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5945428A (en) * | 1996-11-01 | 1999-08-31 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5783579A (en) * | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
| US6063926A (en) * | 1998-11-18 | 2000-05-16 | Schering Corporation | Substituted oximes as neurokinin antagonists |
| CN1181069C (zh) * | 1998-12-23 | 2004-12-22 | 先灵公司 | 新的法尼基蛋白转移酶抑制剂 |
| US6204265B1 (en) * | 1998-12-23 | 2001-03-20 | Schering Corporation | Substituted oximes and hydrazones as neurokinin antagonists |
| ES2237408T3 (es) | 1999-01-25 | 2005-08-01 | Smithkline Beecham Corporation | Antiandrogenos y procedimientos para tratar una enfermedad. |
| AU1413301A (en) * | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
| AR036492A1 (es) * | 2001-09-06 | 2004-09-15 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
-
2002
- 2002-10-15 MX MXPA04003611A patent/MXPA04003611A/es active IP Right Grant
- 2002-10-15 PE PE2002001016A patent/PE20030705A1/es not_active Application Discontinuation
- 2002-10-15 US US10/271,358 patent/US6969718B2/en not_active Expired - Fee Related
- 2002-10-15 EP EP02773770A patent/EP1436281B1/de not_active Expired - Lifetime
- 2002-10-15 AR ARP020103851A patent/AR036812A1/es unknown
- 2002-10-15 CA CA2463626A patent/CA2463626C/en not_active Expired - Fee Related
- 2002-10-15 WO PCT/US2002/032979 patent/WO2003033487A1/en not_active Ceased
- 2002-10-15 JP JP2003536227A patent/JP4309761B2/ja not_active Expired - Fee Related
- 2002-10-15 ES ES02773770T patent/ES2347643T3/es not_active Expired - Lifetime
- 2002-10-15 CN CNA02820557XA patent/CN1571782A/zh active Pending
- 2002-10-15 AT AT02773770T patent/ATE471315T1/de not_active IP Right Cessation
- 2002-10-15 DE DE60236743T patent/DE60236743D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04003611A (es) | 2004-07-30 |
| DE60236743D1 (de) | 2010-07-29 |
| AR036812A1 (es) | 2004-10-06 |
| CN1571782A (zh) | 2005-01-26 |
| EP1436281A1 (de) | 2004-07-14 |
| CA2463626C (en) | 2011-05-24 |
| EP1436281B1 (de) | 2010-06-16 |
| WO2003033487A1 (en) | 2003-04-24 |
| CA2463626A1 (en) | 2003-04-24 |
| JP4309761B2 (ja) | 2009-08-05 |
| PE20030705A1 (es) | 2003-08-21 |
| US20030232837A1 (en) | 2003-12-18 |
| ES2347643T3 (es) | 2010-11-03 |
| JP2005506356A (ja) | 2005-03-03 |
| US6969718B2 (en) | 2005-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| ATE471315T1 (de) | Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE602004018338D1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
| DE60237725D1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| ATE458753T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| DE60223694D1 (de) | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums | |
| ATE274494T1 (de) | Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen | |
| DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| DE60216122D1 (de) | Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen | |
| ATE410421T1 (de) | P38 inhibitor und anwendungsverfahren dafür | |
| ATE385794T1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
| DE60108080D1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
| DE60223715D1 (de) | Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten | |
| DE60122196D1 (de) | Synergistische antioxidans-kombination von delta tocols und polyphenolen | |
| ATE434444T1 (de) | Vorbeugung und behandlung von amyloidogenischen krankheiten | |
| EE200200442A (et) | Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks | |
| ATE362928T1 (de) | 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten | |
| DE60140516D1 (de) | Behandlung von fluorkohlenstoff- ausgangsmaterialien | |
| DE60214542D1 (de) | Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks | |
| DE60106968D1 (de) | Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren | |
| DE60134009D1 (de) | Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose | |
| PL357674A1 (pl) | Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią | |
| MA28176A1 (fr) | Inhibiteurs de la forme mutante du kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |